Pancreatic Cancer News and Research

RSS
Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.
New vaccine reprograms pancreatic tumors and makes them vulnerable to immunotherapy

New vaccine reprograms pancreatic tumors and makes them vulnerable to immunotherapy

Investigators study new cancer immunotherapy to help patients with advanced pancreatic cancer

Investigators study new cancer immunotherapy to help patients with advanced pancreatic cancer

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Blood oxygen sensor attached to endoscope identifies pancreatic cancer

Blood oxygen sensor attached to endoscope identifies pancreatic cancer

New drug shows promising results in patients with advanced pancreatic cancer

New drug shows promising results in patients with advanced pancreatic cancer

Rice, MD Anderson researchers refine technique for attacking hard-to-reach tumors

Rice, MD Anderson researchers refine technique for attacking hard-to-reach tumors

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

NantHealth to unveil open Clinical Operating System at NHS Confederation Annual Conference and Exhibition

NantHealth to unveil open Clinical Operating System at NHS Confederation Annual Conference and Exhibition

UIC conducts clinical trial to evaluate three-drug combination therapy for advanced pancreatic cancer

UIC conducts clinical trial to evaluate three-drug combination therapy for advanced pancreatic cancer

CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM presented at ASCO 2014

CRS-207 and chemotherapy combination Phase 1b trial data for unresectable MPM presented at ASCO 2014

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

Scientists explain how green tea may work to reduce risk of cancer

Scientists explain how green tea may work to reduce risk of cancer

Researchers create initial catalog of human proteome, identify 193 novel proteins

Researchers create initial catalog of human proteome, identify 193 novel proteins

Researchers identify mutated gene common to rare form of pancreatic cancer

Researchers identify mutated gene common to rare form of pancreatic cancer

Eliminating scar tissue, inflammation may make tumors more deadly, find researchers

Eliminating scar tissue, inflammation may make tumors more deadly, find researchers

Mayo Clinic study provides key insights into aggressive form of pancreatic cancer

Mayo Clinic study provides key insights into aggressive form of pancreatic cancer

Research provides key insights into most aggressive form of pancreatic cancer

Research provides key insights into most aggressive form of pancreatic cancer

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

Bacteria in saliva may be indicative of pancreatic cancer

Bacteria in saliva may be indicative of pancreatic cancer

Tubal ligation and breastfeeding may lower risk of ovarian cancer in women with BRCA gene mutations

Tubal ligation and breastfeeding may lower risk of ovarian cancer in women with BRCA gene mutations

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.